CSF analysis was performed in 123 (78.8%) patients, at a median of 5 (IQR, 2–14) days after symptom onset, and “cytoalbuminological dissociation” was observed in 85 (69.1%) patients.

(Table (Table2).2). CSF protein concentration was increased in 44 (59.5%) patients at < 8 days, 19 (82.6%) patients at 8 – 14 days, and 22 (84.6%) patients at > 14 days after disease onset. FVC was available from 84 (53.8%) patients at admission. Less than a third of these patients had a low FVC, defined as FVC < 1.5 L or 20 mL/kg. Nerve root enhancement was observed in 32 (42.7%) of the 75 patients who had spinal cord magnetic resonance imaging. Nerve conduction study (NCS) reports were available from 146 (93.6%) patients, and the procedure was performed at a median of 10 (IQR 5–20) days after symptom onset. Of these patients, 55 (37.7%) were considered to have AIDP, 43 (29.5%) were considered to have AMAN, 28 (19.2%) were considered to have AMSAN, and 9 (6.2%) were considered as equivocal, Table Table22.

Laboratory and electrophysiological features, therapy, and outcome of patients with GBS

AIDP acute inflammatory demyelinating polyradiculoneuropathy, AMAN acute motor axonal neuropathy, AMSAN acute motor-sensory axonal neuropathy, IVIg intravenous immunoglobulin, MFS Miller-Fisher syndrome, N number of patients for whom data are available, PLEX plasma exchange

aMedian time after the onset of symptoms = 5 (2–14) days, and maximum CSF cell count = 23 cells/µl

bMedian time after the onset of symptoms = 10 (5–20) days

cMedian time after the onset of symptoms = 7 (4–13.75) days

dMedian time after first therapy = 17 (8.5–28.5) days

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.